Delivery Order SPE2DB20D1047-SPE2DB25FF79P
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $8,123.96 on June 9, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 1, 2025. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7s) on August 26, 2025, with an ultimate completion date of September 17, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, valued at $8,118.08. This is a firm fixed-price delivery order with an ultimate completion date of June 17, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ibrance 125 mg tablets (7-count) under a firm fixed-price contract with a ceiling value of $8,118.08 and an ultimate completion date of September 8, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 100 mg tablets (quantity 7s) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with a completion date of September 30, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF79PDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,236.16 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count units) on August 25, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement that runs through December 2026 and serves as the primary vehicle for global pharmaceutical supply to military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a comprehensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. The company's extensive federal contract portfolio with the DLA reflects its capability to meet competitive procurement requirements across multiple therapeutic domains. Ibrance, a brand-name oncology medication, is supplied through the pharmaceutical prime vendor program, which enables flexible fulfillment of medical supply needs for customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 8/25/25 |